Somavaratan - Versartis

Drug Profile

Somavaratan - Versartis

Alternative Names: hGH-rPEG - Versartis; hGH-XTEN; Human growth hormone-XTEN - Amunix; Recombinant human growth hormone long-acting - Versartis; Somatropin long-acting - Versartis; VRS-317

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Versartis
  • Developer Teijin Pharma; Versartis
  • Class Growth hormones; Hormonal replacements; Recombinant fusion proteins
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 26 Oct 2017 Versartis and Teijin Pharma terminate the phase III J14VR5 trial in Somatotropin deficiency (In children) in Japan (NCT02413138; 9225296)
  • 21 Sep 2017 Top-line efficacy and adverse events data from the phase III VELOCITY trial in Somatotropin deficiency released by Versartis
  • 23 Aug 2017 Versartis completes the the VELOCITY trial in Somatotropin deficiency (In children, Treatment-naive) in USA, Canada, Belgium, Poland, the Netherlands and Sweden (SC) (NCT02339090) (EudraCT2014-004525-41)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top